A series of pharmacokinetic studies of ceftaroline fosamil in select populations: Normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis

Journal of Clinical Pharmacology

Volumn 54, Issue 7, 2014, Pages 742-752

  Riccobene, Todd ^a   Jakate, Abhijeet ^a   Rank, Doug ^b  

^a FOREST RESEARCH INSTITUTE   (United States)

^b Cerexa Inc   (United States)

Author keywords

ceftaroline fosamil; cephalosporin; pharmacokinetic; Staphylococcus aureus; Streptococcus pneumoniae

Indexed keywords

CEFTAROLINE; CEFTAROLINE FOSAMIL; PLACEBO; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PPI-0903; PRODRUG;

ABNORMAL LABORATORY RESULT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; END STAGE RENAL DISEASE; FEMALE; GROUPS BY AGE; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; MUSCLE SPASM; MYALGIA; NORMAL HUMAN; PERIPHERAL EDEMA; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SEVERE RENAL IMPAIRMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; AGING; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFECTS; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; KIDNEY FAILURE; KIDNEY FAILURE, CHRONIC; METABOLISM; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RENAL REPLACEMENT THERAPY; SEVERITY OF ILLNESS INDEX; URINARY EXCRETION; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGING; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; PRODRUGS; RENAL DIALYSIS; RENAL ELIMINATION; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84901989096     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.265     Document Type: Article

References (22)

1. Ge Y, Biek D, Talbot GH, Sahm DF,. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob. Agents Chemother. 2008; 52: 3398-3407.
2. Jones RN, Farrell DJ, Mendes RE, Sader HS,. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimicrob Chemother. 2011; 66 (suppl 3): iii69-iii80.
3. Sader HS, Fritsche TR, Jones RN,. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2008; 52: 1153-1155. (Pubitemid 351358404)
4. Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN,. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother. 2005; 49: 3501-3512. (Pubitemid 41060605)
5. Biek D, Critchley IA, Riccobene TA, Thye DA,. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. J Antimicrob Chemother. 2010; 65 (suppl 4): iv9-iv16.
6. Villegas-Estrada A, Lee M, Hesek D, Vakulenko SB, Mobashery S,. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA β-lactam antibiotics. J Am Chem Soc. 2008; 130: 9212-9213. (Pubitemid 352031115)
7. Zhanel GG, Sniezek G, Schweizer F, et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs. 2009; 69: 809-831.
8. Kosowska-Shick K, McGhee PL, Appelbaum PC,. Affinity of ceftaroline and other β-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010; 54: 1670-1677.
9. Llarrull LI, Fisher JF, Mobashery S,. Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new β-lactams that meet the challenge. Antimicrob Agents Chemother. 2009; 53: 4051-4063.
10. Moisan H, Pruneau M, Malouin F,. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother. 2010; 65: 713-716.
11. Clinical and Laboratory Standards Institute,. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement (M100-S20). Wayne, PA: Clinical and Laboratory Standards Institute. 2010.
12. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010; 51: 641-650.
13. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010; 51: 1395-1405.
14. Ge Y, Redman R, Floren L, Liao S, Wikler M,. Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects [poster A-1936]. Presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 27-30, 2006; San Francisco, CA.
15. Ge Y, Redman R, Floren L, Liao S, Wikler M,. The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (IV) infusions [poster A-1937]. Presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 27-30, 2006; San Francisco, CA.
16. Ge Y, Thye D, Liao S, Talbot GH,. Pharmacokinetics (PK) of ceftaroline (PPI-0903) in subjects with mild or moderate renal impairment (RI) [poster A-1939]. Presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 27-30, 2006; San Francisco, CA.
17. Riccobene T, Jakate A, Rank D, Thye D,. Open-label pharmacokinetic, safety, and tolerability study of single intravenous doses of ceftaroline in healthy elderly and healthy young adult subjects [poster 3-161]. Presented at the 44th Annual Meeting of the American Society of Health-System Pharmacists (ASHP); December 6-10, 2009, Las Vegas, NV.
18. Riccobene T, Fang E, Thye D,. An open-label pharmacokinetic (PK), safety, and tolerability study of single intravenous (IV) doses of ceftaroline (CPT) in subjects with normal renal function or severe renal impairment [poster A-1003]. Presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 12-15, 2009, San Francisco, CA.
19. Riccobene T, Jakate A, Rank D, Thye D,. An open-label, pharmacokinetic, safety and tolerability study of single-dose intravenous ceftaroline in subjects with end-stage renal disease on intermittent haemodialysis [poster P1455]. Presented at the 19th Annual Meeting of the European Congress of Clinical Microbiology and Infectious Diseases; May 16-19, 2009, Helsinki, Finland.
20. Teflaro (prescribing information). New York, NY: Forest Laboratories Inc. 2012.
21. Van Wart SA, Ambrose PG, Rubino CM, et al. Pharmacokinetic- pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2013 November 25. [Epub ahead of print].
22. Van Wart SA, Forrest A, Khariton T, et al. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. J Clin Pharmacol. 2013; 53: 1155-1167.